Shanghai Junshi Biosciences Co.Ltd(688180) : vv116 compared with paxlovid in the early treatment of mild to moderate covid-19, the phase III registered clinical study reached the primary end point

. The company will communicate with the regulatory authorities on the submission of new drug listing applications in the near future.

- Advertisment -